Exelixis
EXEL
#1827
Rank
โ‚น1.060 T
Marketcap
โ‚น3,956
Share price
-1.20%
Change (1 day)
23.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น215.82. In 2023 the company made an earnings per share (EPS) of โ‚น59.24 an increase over its 2022 EPS that were of โ‚น51.69.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น59.2414.61%
2022โ‚น51.69-22.97%
2021โ‚น67.10100%
2020โ‚น33.55-65.09%
2019โ‚น96.12-53.91%
2018โ‚น208.57333.96%
2017โ‚น48.06-260.61%
2016-โ‚น29.92-58.75%
2015-โ‚น72.54-42.45%
2014-โ‚น126.055.3%
2013-โ‚น119.70

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น1,010 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น123.33-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,299 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น187.27-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น662.58 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น269.32 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น341.69 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น332.80-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น76.17-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA